false
0001610853
0001610853
2025-09-22
2025-09-22
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 22, 2025
Helius Medical Technologies, Inc.
(Exact Name of Registrant as Specified in Charter)
| Delaware |
|
001-38445 |
|
36-4787690 |
(State or Other Jurisdiction |
|
(Commission | | (IRS
Employer |
| of Incorporation) |
|
File Number) |
|
Identification No.) |
|
642 Newtown Yardley Road, Suite
100
Newtown, PA |
|
18940 |
| (Address of Principal Executive Offices) |
|
(Zip
Code) |
Registrant’s Telephone Number, Including Area Code: (215) 944-6100
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Class A
Common Stock, par value $0.0001 |
|
HSDT |
|
The
Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth
company ¨
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01. Regulation FD Disclosure.
On September 22, 2025, Helius Medical Technologies, Inc.
(the “Company”) issued a press release. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated
herein by reference.
Item 9.01 Financial Statements and Exhibits
| Exhibit No. |
|
Description |
| 99.1 |
|
Press Release, dated September 22,
2025 |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| Date: September 22, 2025 |
Helius Medical Technologies, Inc. |
| |
|
|
| |
By: |
/s/ Joseph Chee |
| |
Name: |
Joseph Chee |
| |
Title: |
Executive Chairman |
